Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Published in: Indian Journal of Hematology and Blood Transfusion 1/2016

01-06-2016 | Case Report

All-Trans-Retinoic-Acid Unmasking Hypercalcemia of Hyperparathyroidism

Authors: Uday Yanamandra, Kamal Kant Sahu, Alka Khadwal, Gaurav Prakash, Subhash Chander Varma, Pankaj Malhotra

Published in: Indian Journal of Hematology and Blood Transfusion | Special Issue 1/2016

Login to get access

Abstract

We present a patient of acute promyelocytic leukaemia managed with all-trans-retinoic-acid and arsenic trioxide who developed hypercalcemia with target organ damage. The patient also was simultaneously discovered to be symptomatic from hyperparathyroidism, which was unmasked after ATRA administration. Patient was successfully managed without any interruption of ATRA therapy and parathyroidectomy. We discuss the mechanisms of ATRA in causing hypercalcemia and its possible role in index case in unmasking hyperparathyroidism. Present case refutes Occam’s razor and emphasise that known adverse effects shouldn’t withhold clinicians from working up for other common causes for a given condition.
Literature
1.
Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L et al (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72(2):567–572PubMed
2.
Suzumiya J, Asahara F, Katakami H, Kimuran N, Hisano S, Okumura M et al (1994) Hypercalcaemia caused by all-trans retinoic acid treatment of acute promyelocytic leukaemia: case report. Eur J Haematol 53(2):126–127CrossRefPubMed
3.
Sakakibara M, Ichikawa M, Amano Y, Matsuzawa S, Agematsu K, Mori T et al (1993) Hypercalcemia associated with all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Leuk Res 17(5):441–443CrossRefPubMed
4.
Sakamoto O, Yoshinari M, Rikiishi T, Fujiwara I, Imaizumi M, Tsuchiya S et al (2001) Hypercalcemia due to all-trans retinoic acid therapy for acute promyelocytic leukemia: a case report of effective treatment with bisphosphonate. Pediatr Int 43(6):688–690CrossRefPubMed
5.
Niesvizky R, Siegel DS, Busquets X, Nichols G, Muindi J, Warrell RP Jr et al (1995) Hypercalcaemia and increased serum interleukin-6 levels induced by all-trans retinoic acid in patients with multiple myeloma. Br J Haematol 89(1):217–218CrossRefPubMed
6.
Chertow BS, Williams GA, Norris RM, Baker GR, Hargis GK (1977) Vitamin A stimulation of parathyroid hormone: interactions with calcium, hydrocortisone, and vitamin E in bovine parathyroid tissues and effects of vitamin A in man. Eur J Clin Invest 7(4):307–314CrossRefPubMed
7.
Nagasawa M, Okawa H (1994) All-trans retinoic acid induced hypercalcemia in a patient with acute promyelocytic leukemia: its relation to increased PTH-rP. Int J Hematol 59(2):143–144PubMed
8.
Cordoba R, Ramirez E, Lei SH, Lopez de la Guia A, Sanjurjo MJ, Carcas AJ et al (2008) Hypercalcemia due to an interaction of all-trans retinoic acid (ATRA) and itraconazole therapy for acute promyelocytic leukemia successfully treated with zoledronic acid. Eur J Clin Pharmacol 64(10):1031–1032CrossRefPubMed
9.
Bennett MT, Sirrs S, Yeung JK, Smith CA (2005) Hypercalcemia due to all trans retinoic acid in the treatment of acute promyelocytic leukemia potentiated by voriconazole. Leuk Lymphoma 46(12):1829–1831CrossRefPubMed
10.
Lemez P (1995) Hypercalcaemia caused by all-trans retinoic acid (ATRA) treatment in a case of acute promyelocytic leukaemia was manageable after decreasing the ATRA dose to 27 mg/m2/day. Eur J Haematol 55(4):275–276CrossRefPubMed
Metadata
Title
All-Trans-Retinoic-Acid Unmasking Hypercalcemia of Hyperparathyroidism
Authors
Uday Yanamandra
Kamal Kant Sahu
Alka Khadwal
Gaurav Prakash
Subhash Chander Varma
Pankaj Malhotra
Publication date
01-06-2016
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue Special Issue 1/2016
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-015-0587-1

Other articles of this Special Issue 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Go to the issue

Case Report

Acquired Platelet Dysfunction with Eosinophilia (APDE) Syndrome: A Case Report

Case Report

Acute Lymphoblastic Leukemia in the Course of Polycythemia Vera: A Case Report and Review of Literature

Correspondence

Antiphospholipid Antibodies in Indian Women with Spontaneous, Recurrent Fetal Loss

Case Report

Familial Pelger–Huet Anomaly

Images

Bullae And Blisters: A Rare Case of Bendamustine Skin Toxicity

Case Report

Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits